| ClinicalTrials Identifier: | NCT02566993 |
|---|
| Updated: | 2016_04_04 |
|---|
 Descriptive Information
|
|---|
| Brief title | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer |
|---|
| Official title | Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) |
|---|
| Brief summary |
|---|
| Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line to determine a difference in progression-free survival (PFS) by an Independent Review Committee (IRC) between lurbinectedin (PM01183)/doxorubicin (DOX) and the control arm (CAV) or topotecan and to analyze the median overall survival (OS) and mid- and long-term overall survival (OS at 12, 18 and 24 months). |
| Detailed description |
|---|
|
| Phase | Phase 3 |
|---|
| Study type | Interventional |
|---|
| Study design | Treatment |
|---|
| Study design | Randomized
...
Administrative Data
|
|---|
| Organization name | PharmaMar |
|---|
| Organization study ID | PM1183-C-003-14 |
|---|
| Sponsor | PharmaMar |
|---|
| Health Authority | United States: Food and Drug Administration |
|---|
Recruitment
Information :
|
|---|
| Status : | Not yet recruiting
|
|---|
| Start date : | 2016-06
|
|---|
Primary completion date :
|
2019-06 (Anticipated)
...
|
|---|
|
|---|